Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients

dc.contributor.authorErkin E.F.
dc.contributor.authorÇelik P.
dc.contributor.authorKayikçioǧlu Ö.
dc.contributor.authorDeveci H.M.
dc.contributor.authorŞakar A.
dc.date.accessioned2024-07-22T08:23:27Z
dc.date.available2024-07-22T08:23:27Z
dc.date.issued2006
dc.description.abstractAims: To investigate the cardiovascular and respiratory effects of topical latanoprost 0.005% and topical betaxolol 0.25% monotherapy in newly diagnosed glaucoma patients. Methods: Forty newly diagnosed glaucoma patients were enrolled in this prospective, observer-masked, randomized, parallel study. Patients received either latanoprost 0.005% or betaxolol 0.25% for a duration of 3 months. Baseline evaluation included intraocular pressure (IOP) measurement and cardiorespiratory examinations including pulse rate, systolic and diastolic blood pressure measurements and spirometry. These measurements were repeated after 3 months. Results: Both latanoprost and betaxolol reduced IOP significantly (p = 0.001). After 3 months of therapy, the mean pulse rate, systolic and diastolic blood pressure values of the betaxolol group were reduced (p = 0.027, p = 0.07 and p = 0.016, respectively). No significant changes occurred in the cardiovascular measurements of the latanoprost group (p > 0.05). There were no significant changes in any of the spirometric measurements tested for both groups (p > 0.05). Conclusion: Both latanoprost and betaxolol are safe concerning respiratory functions. Betaxolol may cause small changes in the cardiovascular system, suggesting that blood pressure and pulse rates should be checked before and in regular intervals after prescribing it for the elderly. Latanoprost seems to be a safe medication in view of absence of systemic cardiovascular and respiratory side effects. Copyright © 2006 S. Karger AG.
dc.identifier.DOI-ID10.1159/000094625
dc.identifier.issn00303755
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19549
dc.language.isoEnglish
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntihypertensive Agents
dc.subjectBetaxolol
dc.subjectBlood Pressure
dc.subjectCardiovascular System
dc.subjectFemale
dc.subjectGlaucoma, Open-Angle
dc.subjectHeart Rate
dc.subjectHumans
dc.subjectIntraocular Pressure
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectProspective Studies
dc.subjectProstaglandins F, Synthetic
dc.subjectRespiration
dc.subjectSpirometry
dc.subjectbetaxolol
dc.subjectlatanoprost
dc.subjectarticle
dc.subjectcardiovascular effect
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdiastolic blood pressure
dc.subjectdrug effect
dc.subjectfemale
dc.subjectglaucoma
dc.subjecthuman
dc.subjectintraocular pressure
dc.subjectmale
dc.subjectpulse rate
dc.subjectrandomized controlled trial
dc.subjectrespiratory function
dc.subjectspirometry
dc.subjectsystolic blood pressure
dc.subjecttreatment outcome
dc.titleEffects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients
dc.typeArticle

Files